查詢結果分析
來源資料
相關文獻
- 最大概似估計式與最小變方不偏估計式在評估平均生体相等性之比較
- 集合住宅屬性與設施管理之決策關係研究
- A Review on in Vitro Studies of Hemodynamic Characteristics in Terminal and Lateral Aneurysm Models
- 平均反應模式參數估值有關之模擬研究--比較加權最小平方法與最大概度法兩種估值之變異
- 都市景觀電腦視覺模擬之課題探討--以臺南市為例
- 不同水氣垂直結構的颮線模擬測試
- Synthetic Wide-angle Seismic Data in Gas Hydrate and Free Gas Bearing Sediments: A Virtual OBS Case Study
- Gradient Projection Confidence Intervals in Nonlinear Regression
- 因素分析次序資料時選擇:皮爾遜相關或多序類相關?
- Estimating the Latent Trait from Likert-Type Data: A Comparison of Factor Analysis, Item Response Theory, and Multidimensional Scaling
頁籤選單縮合
題名 | 最大概似估計式與最小變方不偏估計式在評估平均生体相等性之比較=Comparison of MLE and MVUE for Evaluation of Avrage Bioequivalence |
---|---|
作者 | 劉仁沛; 許富閔; Liu, Jen-pei; Xu, Fu-min; |
期刊 | 中國統計學報 |
出版日期 | 20050900 |
卷期 | 43:3 民94.09 |
頁次 | 頁239-258 |
分類號 | 319.5 |
語文 | chi |
關鍵詞 | 平均生体相等性; 模擬研究; 經驗型誤; 經驗檢定力; 信賴區間包含率; Average bioequivalence; Simulation study; Empirical size; Empirical power; Probability coverage; |
中文摘要 | 原廠藥研發需要花費巨大財力與長期投資,所以原廠藥藥價是非常昂貴。待原廠藥專利期滿後,其它藥廠則可仿造相同藥品,這種仿照藥稱為學名藥,因學名藥不須長期研發投資,所以學名藥價格較原廠藥為便宜。因此可節省醫療費用的支出。為確保學名藥的療效和安全性與原廠藥相同,藥政單位要求廠商必須証明學名藥與原廠藥具有平均生体相等性後才核准上市。最大概似估計式已被採用在評估平均生体相等性但最大概似估計式會高估平均生体相等性。所以我們建議採用最小變方不偏估計式評估平均生体相等性。我們並執行一個模擬研究經,以經驗型I誤差與經驗檢定力來比較兩種估計式之優劣。我們亦以實際資料說明最小變方不偏估計式在評估生体相等性上的應用。 |
英文摘要 | The research and development of an innovative drug product takes 10-12 years and 800 millions to 1 billion US dollars. Therefore, it is a costly, time-consuming, and highly risky endeavor. One way to reduce the drug cost is to introduce generic drugs after the patent of the innovative drugs expires. Currently, most regulatory agencies in the world only require evidence of average bioequivalence from in vivo bioequivalence trials to approve the generic drugs. Currently, most of heath regulatory agencies in the world such as the U.S. Food and Drug Administration and Taiwan Department of Heath use maximum likelihood estimator (MLE) for evaluation of average bioequivalence. Since MLE is not an unbiased estimator for the relative bioavailability, therefore, we propose the minimum variance unbiased estimator (MVUE) to assess the average bioequivalence. We performed a simulation study to compare the bias, mean square error, empirical size, empirical power and probability coverage between MLE and MVUE on the various combinations of parameters and sample size under 2 x 2 crossover design and higher-order crossover design. The simulation results showed that in addition to unbiasedness, the size and power of the MVUE is comparable to those of MLE. A numerical example illustrates the procedure of the MVUE for evaluation of average bioequivalence. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。